VR Logo

Pliant Therapeutics Inc. (PLRX) download report


Healthcare | Biotechnology & Pharma Research

Pliant Therapeutics Inc. (PLRX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.

IPO Date: 03-Jun-2020

Pres, CEO & Director: Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.

Chief Financial Officer: Dr. Keith Lamont Cummings M.B.A., M.D.

Listing: NASDAQ: PLRX

Country: United States

Headquarters: South San Francisco, CA

Website: https://pliantrx.com

Key Facts

Market cap: $277.78 Mln

Revenue (TTM): $6.65 Mln

Earnings (TTM): $-102.51 Mln

Cash: $178.28 Mln

Total Debt: $6.92 Mln

Insider's Holding: 8.96%

Liquidity: Low

52 Week range: $3.97 - 29.35

Shares outstanding: 36,169,500

5 Years Aggregate:

  • CFO: $-160.72 Mln
  • EBITDA: $-165.45 Mln
  • Net Profit: $-169.70 Mln

Stock Performance

Time Period Pliant Therapeutics (PLRX) S&P BSE Sensex S&P Small-Cap 600
YTD-43.19-9.18-18.78
1 month36.72-4.78-8.00
3 months9.42-9.66-13.65
1 Year-73.660.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Pliant Therapeutics (PLRX) S&P Small-Cap 600 S&P BSE Sensex
2021-40.5825.2721.99